Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients

Re-treatment with interferon-alpha alone for chronic hepatitis C nonresponders to interferon-alpha monotherapy is almost ineffective. This multicentre, randomized, parallel-group, dose-finding study evaluated the efficacy of interferon-beta-1a in the treatment of chronic hepatitis C patients unrespo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of viral hepatitis 2004-09, Vol.11 (5), p.418-426
Hauptverfasser: Cheng, P-N, Marcellin, P, Bacon, B, Farrell, G, Parsons, I, Wee, T, Chang, T-T
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 426
container_issue 5
container_start_page 418
container_title Journal of viral hepatitis
container_volume 11
creator Cheng, P-N
Marcellin, P
Bacon, B
Farrell, G
Parsons, I
Wee, T
Chang, T-T
description Re-treatment with interferon-alpha alone for chronic hepatitis C nonresponders to interferon-alpha monotherapy is almost ineffective. This multicentre, randomized, parallel-group, dose-finding study evaluated the efficacy of interferon-beta-1a in the treatment of chronic hepatitis C patients unresponsive to interferon-alpha. A total of 267 patients were randomized to one of four groups: subcutaneous interferon-beta-1a 12 MIU (44 microg) or 24 MIU (88 microg) administered three times weekly or daily. Patients were treated for 48 weeks and then followed up for an additional 24 weeks. There was a trend towards a dose-response relationship regarding virological [loss of detectable serum hepatitis C virus (HCV) RNA] and biochemical response (normalization of serum alanine aminotransferase). Overall, 22 patients (8.3%) had a virological response at the end of treatment; nine patients (3.4%) had a sustained virological response (SVR). Strikingly, 21.7% (5/23) of Chinese patients achieved SVR. Univariate analysis revealed that race was the only variable related to SVR [odds ratio (OR) 16.6; 95% CI 4.1-67.3; P < 0.0001]. Multiple logistic regression analysis also confirmed that more Chinese patients achieved SVR than non-Chinese patients (OR 12.3; 95% CI 2.6-59.3; P = 0.0017). In addition, complete clearance of HCV-RNA occurred earlier in Chinese than in non-Chinese responders (median 2 vs 30 weeks; P = 0.020). Thirty-six patients were withdrawn from treatment because of adverse events. Most adverse events were mild or moderate in severity. In conclusion, interferon-beta-1a provided considerable clinical benefit in Chinese patients with chronic hepatitis C unresponsive to interferon-alpha. The evaluation of interferon-beta-1a in this setting is progressing.
doi_str_mv 10.1111/j.1365-2893.2004.00514.x
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_66861060</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66861060</sourcerecordid><originalsourceid>FETCH-LOGICAL-p170t-ffcb40a0a88b6fb80d91a7e57ef2f697271e6ca215546ad180adee8b9b3cfde63</originalsourceid><addsrcrecordid>eNqFUM1KxDAQDqK4uvoKkpO31iRt0qw3Kf7BgiB6LtN2QrN029qkou_hA5viugcvzmW-me9nYAihnMU81NUm5omSkdCrJBaMpTFjkqfxxwE52ROHM5YiYpKlC3Lq3IYxngjJj8mCy0RmKlUn5OsZKgstra0xOGJXoaO2oyO6oe9cGHwfZo9jYPsuKtFDxGGWVE1Y2Io2OIC33jqa06nbGe07_nFCOzRwTYGGiLDcX5ij8sZ2GOAchJ13Z-TIQOvwfNeX5PXu9iV_iNZP94_5zToaeMZ8ZExVpgwYaF0qU2pWrzhkKDM0wqhVJjKOqgLBpUwV1FwzqBF1uSqTytSokiW5_Mkdxv5tQueLrXUVti102E-uUEorzhT7V8izjGuZiiC82Amncot1MYx2C-Nn8fvw5BtTmYgq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17718542</pqid></control><display><type>article</type><title>Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Cheng, P-N ; Marcellin, P ; Bacon, B ; Farrell, G ; Parsons, I ; Wee, T ; Chang, T-T</creator><creatorcontrib>Cheng, P-N ; Marcellin, P ; Bacon, B ; Farrell, G ; Parsons, I ; Wee, T ; Chang, T-T</creatorcontrib><description>Re-treatment with interferon-alpha alone for chronic hepatitis C nonresponders to interferon-alpha monotherapy is almost ineffective. This multicentre, randomized, parallel-group, dose-finding study evaluated the efficacy of interferon-beta-1a in the treatment of chronic hepatitis C patients unresponsive to interferon-alpha. A total of 267 patients were randomized to one of four groups: subcutaneous interferon-beta-1a 12 MIU (44 microg) or 24 MIU (88 microg) administered three times weekly or daily. Patients were treated for 48 weeks and then followed up for an additional 24 weeks. There was a trend towards a dose-response relationship regarding virological [loss of detectable serum hepatitis C virus (HCV) RNA] and biochemical response (normalization of serum alanine aminotransferase). Overall, 22 patients (8.3%) had a virological response at the end of treatment; nine patients (3.4%) had a sustained virological response (SVR). Strikingly, 21.7% (5/23) of Chinese patients achieved SVR. Univariate analysis revealed that race was the only variable related to SVR [odds ratio (OR) 16.6; 95% CI 4.1-67.3; P &lt; 0.0001]. Multiple logistic regression analysis also confirmed that more Chinese patients achieved SVR than non-Chinese patients (OR 12.3; 95% CI 2.6-59.3; P = 0.0017). In addition, complete clearance of HCV-RNA occurred earlier in Chinese than in non-Chinese responders (median 2 vs 30 weeks; P = 0.020). Thirty-six patients were withdrawn from treatment because of adverse events. Most adverse events were mild or moderate in severity. In conclusion, interferon-beta-1a provided considerable clinical benefit in Chinese patients with chronic hepatitis C unresponsive to interferon-alpha. The evaluation of interferon-beta-1a in this setting is progressing.</description><identifier>ISSN: 1352-0504</identifier><identifier>EISSN: 1365-2893</identifier><identifier>DOI: 10.1111/j.1365-2893.2004.00514.x</identifier><identifier>PMID: 15357646</identifier><language>eng</language><publisher>England</publisher><subject>Adolescent ; Adult ; Aged ; Antiviral Agents - administration &amp; dosage ; Antiviral Agents - therapeutic use ; Asian Continental Ancestry Group ; Female ; Hepacivirus - drug effects ; Hepatitis C virus ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - ethnology ; Hepatitis C, Chronic - virology ; Humans ; Interferon beta-1a ; Interferon-alpha - therapeutic use ; Interferon-beta - administration &amp; dosage ; Interferon-beta - therapeutic use ; Male ; Middle Aged ; Treatment Failure ; Treatment Outcome</subject><ispartof>Journal of viral hepatitis, 2004-09, Vol.11 (5), p.418-426</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15357646$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheng, P-N</creatorcontrib><creatorcontrib>Marcellin, P</creatorcontrib><creatorcontrib>Bacon, B</creatorcontrib><creatorcontrib>Farrell, G</creatorcontrib><creatorcontrib>Parsons, I</creatorcontrib><creatorcontrib>Wee, T</creatorcontrib><creatorcontrib>Chang, T-T</creatorcontrib><title>Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients</title><title>Journal of viral hepatitis</title><addtitle>J Viral Hepat</addtitle><description>Re-treatment with interferon-alpha alone for chronic hepatitis C nonresponders to interferon-alpha monotherapy is almost ineffective. This multicentre, randomized, parallel-group, dose-finding study evaluated the efficacy of interferon-beta-1a in the treatment of chronic hepatitis C patients unresponsive to interferon-alpha. A total of 267 patients were randomized to one of four groups: subcutaneous interferon-beta-1a 12 MIU (44 microg) or 24 MIU (88 microg) administered three times weekly or daily. Patients were treated for 48 weeks and then followed up for an additional 24 weeks. There was a trend towards a dose-response relationship regarding virological [loss of detectable serum hepatitis C virus (HCV) RNA] and biochemical response (normalization of serum alanine aminotransferase). Overall, 22 patients (8.3%) had a virological response at the end of treatment; nine patients (3.4%) had a sustained virological response (SVR). Strikingly, 21.7% (5/23) of Chinese patients achieved SVR. Univariate analysis revealed that race was the only variable related to SVR [odds ratio (OR) 16.6; 95% CI 4.1-67.3; P &lt; 0.0001]. Multiple logistic regression analysis also confirmed that more Chinese patients achieved SVR than non-Chinese patients (OR 12.3; 95% CI 2.6-59.3; P = 0.0017). In addition, complete clearance of HCV-RNA occurred earlier in Chinese than in non-Chinese responders (median 2 vs 30 weeks; P = 0.020). Thirty-six patients were withdrawn from treatment because of adverse events. Most adverse events were mild or moderate in severity. In conclusion, interferon-beta-1a provided considerable clinical benefit in Chinese patients with chronic hepatitis C unresponsive to interferon-alpha. The evaluation of interferon-beta-1a in this setting is progressing.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antiviral Agents - administration &amp; dosage</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Asian Continental Ancestry Group</subject><subject>Female</subject><subject>Hepacivirus - drug effects</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - ethnology</subject><subject>Hepatitis C, Chronic - virology</subject><subject>Humans</subject><subject>Interferon beta-1a</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Interferon-beta - administration &amp; dosage</subject><subject>Interferon-beta - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Treatment Failure</subject><subject>Treatment Outcome</subject><issn>1352-0504</issn><issn>1365-2893</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUM1KxDAQDqK4uvoKkpO31iRt0qw3Kf7BgiB6LtN2QrN029qkou_hA5viugcvzmW-me9nYAihnMU81NUm5omSkdCrJBaMpTFjkqfxxwE52ROHM5YiYpKlC3Lq3IYxngjJj8mCy0RmKlUn5OsZKgstra0xOGJXoaO2oyO6oe9cGHwfZo9jYPsuKtFDxGGWVE1Y2Io2OIC33jqa06nbGe07_nFCOzRwTYGGiLDcX5ij8sZ2GOAchJ13Z-TIQOvwfNeX5PXu9iV_iNZP94_5zToaeMZ8ZExVpgwYaF0qU2pWrzhkKDM0wqhVJjKOqgLBpUwV1FwzqBF1uSqTytSokiW5_Mkdxv5tQueLrXUVti102E-uUEorzhT7V8izjGuZiiC82Amncot1MYx2C-Nn8fvw5BtTmYgq</recordid><startdate>200409</startdate><enddate>200409</enddate><creator>Cheng, P-N</creator><creator>Marcellin, P</creator><creator>Bacon, B</creator><creator>Farrell, G</creator><creator>Parsons, I</creator><creator>Wee, T</creator><creator>Chang, T-T</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200409</creationdate><title>Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients</title><author>Cheng, P-N ; Marcellin, P ; Bacon, B ; Farrell, G ; Parsons, I ; Wee, T ; Chang, T-T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p170t-ffcb40a0a88b6fb80d91a7e57ef2f697271e6ca215546ad180adee8b9b3cfde63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antiviral Agents - administration &amp; dosage</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Asian Continental Ancestry Group</topic><topic>Female</topic><topic>Hepacivirus - drug effects</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - ethnology</topic><topic>Hepatitis C, Chronic - virology</topic><topic>Humans</topic><topic>Interferon beta-1a</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Interferon-beta - administration &amp; dosage</topic><topic>Interferon-beta - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Treatment Failure</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheng, P-N</creatorcontrib><creatorcontrib>Marcellin, P</creatorcontrib><creatorcontrib>Bacon, B</creatorcontrib><creatorcontrib>Farrell, G</creatorcontrib><creatorcontrib>Parsons, I</creatorcontrib><creatorcontrib>Wee, T</creatorcontrib><creatorcontrib>Chang, T-T</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of viral hepatitis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheng, P-N</au><au>Marcellin, P</au><au>Bacon, B</au><au>Farrell, G</au><au>Parsons, I</au><au>Wee, T</au><au>Chang, T-T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients</atitle><jtitle>Journal of viral hepatitis</jtitle><addtitle>J Viral Hepat</addtitle><date>2004-09</date><risdate>2004</risdate><volume>11</volume><issue>5</issue><spage>418</spage><epage>426</epage><pages>418-426</pages><issn>1352-0504</issn><eissn>1365-2893</eissn><abstract>Re-treatment with interferon-alpha alone for chronic hepatitis C nonresponders to interferon-alpha monotherapy is almost ineffective. This multicentre, randomized, parallel-group, dose-finding study evaluated the efficacy of interferon-beta-1a in the treatment of chronic hepatitis C patients unresponsive to interferon-alpha. A total of 267 patients were randomized to one of four groups: subcutaneous interferon-beta-1a 12 MIU (44 microg) or 24 MIU (88 microg) administered three times weekly or daily. Patients were treated for 48 weeks and then followed up for an additional 24 weeks. There was a trend towards a dose-response relationship regarding virological [loss of detectable serum hepatitis C virus (HCV) RNA] and biochemical response (normalization of serum alanine aminotransferase). Overall, 22 patients (8.3%) had a virological response at the end of treatment; nine patients (3.4%) had a sustained virological response (SVR). Strikingly, 21.7% (5/23) of Chinese patients achieved SVR. Univariate analysis revealed that race was the only variable related to SVR [odds ratio (OR) 16.6; 95% CI 4.1-67.3; P &lt; 0.0001]. Multiple logistic regression analysis also confirmed that more Chinese patients achieved SVR than non-Chinese patients (OR 12.3; 95% CI 2.6-59.3; P = 0.0017). In addition, complete clearance of HCV-RNA occurred earlier in Chinese than in non-Chinese responders (median 2 vs 30 weeks; P = 0.020). Thirty-six patients were withdrawn from treatment because of adverse events. Most adverse events were mild or moderate in severity. In conclusion, interferon-beta-1a provided considerable clinical benefit in Chinese patients with chronic hepatitis C unresponsive to interferon-alpha. The evaluation of interferon-beta-1a in this setting is progressing.</abstract><cop>England</cop><pmid>15357646</pmid><doi>10.1111/j.1365-2893.2004.00514.x</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1352-0504
ispartof Journal of viral hepatitis, 2004-09, Vol.11 (5), p.418-426
issn 1352-0504
1365-2893
language eng
recordid cdi_proquest_miscellaneous_66861060
source MEDLINE; Wiley Journals
subjects Adolescent
Adult
Aged
Antiviral Agents - administration & dosage
Antiviral Agents - therapeutic use
Asian Continental Ancestry Group
Female
Hepacivirus - drug effects
Hepatitis C virus
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - ethnology
Hepatitis C, Chronic - virology
Humans
Interferon beta-1a
Interferon-alpha - therapeutic use
Interferon-beta - administration & dosage
Interferon-beta - therapeutic use
Male
Middle Aged
Treatment Failure
Treatment Outcome
title Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A59%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Racial%20differences%20in%20responses%20to%20interferon-beta-1a%20in%20chronic%20hepatitis%20C%20unresponsive%20to%20interferon-alpha:%20a%20better%20response%20in%20Chinese%20patients&rft.jtitle=Journal%20of%20viral%20hepatitis&rft.au=Cheng,%20P-N&rft.date=2004-09&rft.volume=11&rft.issue=5&rft.spage=418&rft.epage=426&rft.pages=418-426&rft.issn=1352-0504&rft.eissn=1365-2893&rft_id=info:doi/10.1111/j.1365-2893.2004.00514.x&rft_dat=%3Cproquest_pubme%3E66861060%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17718542&rft_id=info:pmid/15357646&rfr_iscdi=true